Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study

BACKGROUND: Recent studies indicate the benefit of treatment with osimertinib over that with conventional epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for untreated EGFR-mutated non-small cell lung cancer (NSCLC). Cobas ver2 is the only companion diagnostic method for det...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Kogo, Mariko, Fujimoto, Daichi, Hosoya, Kazutaka, Nagata, Kazuma, Nakagawa, Atsushi, Tachikawa, Ryo, Yamashita, Daisuke, Kitamura, Yuka, Imai, Yukihiro, Tomii, Keisuke
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006383/
https://ncbi.nlm.nih.gov/pubmed/32028905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6603-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky